Search for content, post, videos

Category

Pharma

magnus-hansson-neurovive
0 COMMENT
39 Views
NeuroVive presents preclinical findings

NeuroVive Pharmaceutical announces positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model. NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also…

medivir-research
0 COMMENT
39 Views
Update on Medivir’s development of JNJ-4178

Medivir communicates an update on the status of the development of JNJ-4178, the triple combination of simeprevir, odalasvir and AL-335, following The International Liver Congress 2017 of the European Association for the Study of the Liver (EASL), which was held in Amsterdam, on 19-23 April. Data from an ongoing phase…

Recipharm-Research-Triangle-Park
0 COMMENT
62 Views
Recipharm opens new GMP suite

Recipharm has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA. The suite, which represents a $750k investment, is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose…

CEO_Tuomas_Tenkanen_GeneSpress
0 COMMENT
166 Views
Mobidiag’s brand hits shelves in Italy

Under the three-year agreement, AB ANALITICA is the exclusive distributor of Mobidiag’s brand Amplidiag in vitro diagnostics for gastrointestinal infections in Italy. AB Analitica is specialized in the development and the sale of diagnostic systems for professional use. “For the past months, we have been significantly extending our in vitro…

Martin-Bonde-vaccibody
0 COMMENT
183 Views
Vaccibody moves forward with clinical study

Norwegian company Vaccibody is moving forward with the first vaccination of a patient with the human papillomavirus, HPV-virus, in a phase IIa study using the company´s immunotherapy platform. The primary objectives of the phase IIa study are to assess T cell mediated immune responses in the peripheral blood and to…

umecrine
0 COMMENT
218 Views
First patient included in Umecrine’s study

Karolinska Development’s portfolio company Umecrine Cognition announces the inclusion of the first patient in a clinical Phase Ib/IIa study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy. The objectives of the study (protocol UCAB-CT-02) are to evaluate the safety and pharmacokinetics of steady-state dosing…

medivir-research
0 COMMENT
169 Views
Positive data from Medivir

Medivir announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat…

per-norlen-foto-jenny-leyman
0 COMMENT
178 Views
Alligator completes Phase I trial

Biotech company Alligator Biosciences has finished its first Phase I clinical trial with the immuno-oncology antibody ADC-1013. CDMO Cobra Biologics has manufactured the antibody as part of the company’s cell line development programme for Alligator. Cobra has developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using their maxXpress…

ascendis_pharma
0 COMMENT
166 Views
Ascendis Pharma presents new data

Ascendis Pharma has announced data supporting its product pipeline presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida. “We are delighted to show the breadth of our growing pipeline at this year’s ENDO conference, including three potentially differentiated treatments for rare endocrine diseases,” said Jonathan…

sean-bohen
0 COMMENT
97 Views
Tagrisso receives US FDA full approval

The US Food and Drug Administration has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR…

research_astrazeneca
0 COMMENT
86 Views
Orphan designation for AstraZeneca

AstraZeneca and its global biologics research and development arm, MedImmune, has announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Developed by MedImmune, inebilizumab is currently in Phase IIb clinical development for NMOSD. “The EMA’s orphan…

Johan_Haggblad
0 COMMENT
211 Views
Positive results from Pharmalink trial

Pharmalink announces that positive results and analyses from the completed Phase 2b trial of its oral drug candidate Nefecon in primary IgA nephropathy (IgAN) patients have been published online in The Lancet. This is the first time the full results from this trial have been published in this format. In…

logistics-of-the-future
0 COMMENT
168 Views
Temperature controlled logistics of the future

A new report highlights upcoming trends in temperature controlled logistics, for example the personalization of the cold chain and cost control, as well as the project to crack the emerging markets of the world. Progression needs to be made in data management and the main issue lies within the organization…